Combination<unk>  regimens using platinum-based<unk>  and specific-inhibitors is the treatment of choice for the management of patients with<unk>  may be required upon histological subtype of<unk>  cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for<unk>  cell carcinoma of the lung is neoadjuvant<unk>  or adjuvant<unk> , followed or preceded by surgical resection. Commonly used<unk> utic agents, include: cisplatin, erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.
Squamous cell carcinoma of the lung chemotherapy
Non small cell lung cancer chemotherapy
Non small cell lung cancer radiation therapy
Non small cell lung cancer medical therapy
Squamous cell carcinoma of the lung medical therapy
Lung cancer medical therapy
Lung mass medical therapy
Small cell carcinoma of the lung medical therapy